Newron Pharmaceuticals Aktie
| 0,00EUR | 0,00EUR | 0,00% |
WKN DE: A0LF18 / ISIN: IT0004147952
Personal
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 0 | 0 | 0 | 0 | 0 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
Bilanz (in Mio. CHF) - Aktiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 41 | 28 | 18 | 57 | 35 |
| Summe Anlagevermögen | 11 | 9 | 6 | 3 | 2 |
| Summe Aktiva | 52 | 37 | 24 | 60 | 37 |
Bilanz (in Mio. CHF) - Passiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 49 | 51 | 52 | 59 | 48 |
| Summe Eigenkapital | 3 | -14 | -28 | 1 | -10 |
| Summe Passiva | 52 | 37 | 24 | 60 | 37 |
Adresse
| via Antonio Meucci 3, 20091 Bresso | |
| Telefon | +39 (02) 610-3461 |
| Fax | +39 (02) 610-34654 |
| Internet | https://www.newron.com/ |
Management
|
Christopher John Martin
Chairman |
|
Dennis Dionne
Vice President-Commercial Affairs |
|
Filippo Moriggia
Vice President-Operations |
|
Gillian Dines
Non-Executive Director |
|
Laura Faravelli
Executive Vice President-Business Development |
|
Luca Benatti
Independent Non-Executive Director |
|
Margarita I. Chavez
Independent Director |
|
Patrick J. Langlois
Independent Non-Executive Director |
|
Ravi Anand
Chief Medical Officer |
|
Roberto Galli
Chief Financial Officer |
|
Stefan Weber
Chief Executive Officer & Director |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.